Genomtec S.A.

Registration Form • Jun 29, 2022

Obtaining patent protection for an invention from the European PatentOffice.The Executive Board of Genomtec S.A. ("Company","Issuer") registered in Wroclaw, Poland, hereby reports that The Companyhas learned about the validity of a patent for an invention entitled _quot;Amethod of detecting genetic material in a biological sample and a devicefor its implementation_quot; in Albania, Austria, Belgium, Bosnia andHerzegovina, Bulgaria, Croatia, Cyprus, Montenegro, Czech Republic,Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland,Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia,Malta, Monaco, Netherlands, Norway, Portugal, Romania, San Marino,Serbia, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom.The Issuer informed about the positive decision regarding granting ofthe patent by the European Patent Office in the report 2/2022, howeverthe final stage granting patent protection in a particular country wasthe validation mentioned above.The invention covers the keytechnical solutions related to the proprietary contactless heating andtemperature detection system developed for POCT platforms, includingGenomtec ID.The Issuer's Management Board decided that thereceipt of the above validation is confidential information, as in thecase of an entity operating on the molecular diagnostics market, it isnecessary to effectively protect intellectual and industrial property.Properly secured intellectual and industrial property may constitute theIssuer's competitive advantage - and its safe commercialization ispossible provided that full protection is ensured on selected markets.Inthe opinion of the Management Board, a high level of intellectualproperty protection will also provide the Company with an appropriatenegotiating position before signing commercial agreements with selectedpartners in the scope of implementing the commercialization strategy.Patentproceedings are aimed at securing key interests and are in line with theIssuer's development strategy, which includes building a portfolio ofintellectual property rights. POCT diagnostics using the Genomtec IDplatform is the key area of the Issuer's operations. For these reasons,in the opinion of the Management Board, this information meets thecriteria of confidential information within the meaning of Art. 7 sec. 1MAR.